RA
CRMD icon

Royce & Associates’s CorMedix CRMD Stock Holding History

Royce & Associates’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$17.1M Buy
2,176,362
+288,830
+15% +$2.28M 0.14% 246
2026
Q1 		$12.8M Buy
1,887,532
+1,645,509
+680% +$12.2M 0.13% 262
2025
Q4 		$2.81M Sell
242,023
-199,289
-45% -$2.2M 0.03% 547
2025
Q3 		$5.13M Buy
+441,312
New +$5.34M 0.05% 465

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Royce & Associates's CRMD Position: Q2 2026 in Review

Royce & Associates increased its CorMedix (CRMD) stake by 15% in Q2 2026, buying an estimated $2.28M and bringing the position to 2,176,362 shares worth $17.1M. The position accounts for 0.14% of the portfolio, ranked #246.

Royce & Associates first reported a position in CRMD in Q3 2025 and has held it in 4 quarters since. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Royce & Associates held 2,176,362 shares of CorMedix worth $17.1M as of Q2 2026.
  • Royce & Associates bought 288,830 CorMedix shares in Q2 2026, an estimated $2.28M.
  • CorMedix made up 0.14% of Royce & Associates's portfolio in Q2 2026, its #246 holding.
  • Royce & Associates first reported a position in CorMedix in Q3 2025 and has held it in 4 quarters since.
  • 194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Royce & Associates's 13F filing for Q2 2026, filed 14 Aug 2026.